Glucosamine and Joint Pain: The Evidence Has Changed
Glucosamine and chondroitin once looked like the answer to knee osteoarthritis, but nearly two decades of research have steadily dismantled that optimism. In the large NIH-funded GAIT trial of 1,583 patients, neither glucosamine, chondroitin, nor the combination beat placebo on the main pain outcome (where 60% of placebo patients responded), while the prescription drug celecoxib did; the often-cited “moderate-to-severe pain” benefit was only a hypothesis-generating subgroup. European trials of pharmaceutical-grade glucosamine sulfate show a smaller effect on joint-space narrowing, so any real benefit is modest and form- and quality-dependent. It is low-risk to try for a few months, but it is not equivalent to an anti-inflammatory drug and is worth stopping if it does not help.
In the early 2000s, glucosamine and chondroitin looked like the answer to osteoarthritis, fuelled by a 2006 New England Journal of Medicine trial that hinted at benefit in patients with moderate-to-severe knee pain. Nearly two decades of follow-up research has systematically dismantled that optimism, and the story of how it unravelled is a useful lesson in reading supplement evidence.
What the GAIT Trial Actually Found
The GAIT trial (Clegg et al., NEJM, 2006) was an NIH-funded multicentre RCT of 1,583 patients with symptomatic knee osteoarthritis randomized to glucosamine 1500 mg/day, chondroitin 1200 mg/day, the combination, celecoxib 200 mg/day, or placebo for 24 weeks. The primary outcome — a 20% reduction in knee pain — was not significantly different for any supplement arm versus placebo (placebo response rate 60.1%). Celecoxib reached significance (10 percentage points above placebo). The widely circulated "moderate-to-severe pain subgroup" benefit was a stratified analysis (n=354) and is hypothesis-generating, not confirmatory.
Glucosamine vs. placebo vs. the updated evidence
The Subsequent Evidence
Multiple large independent trials since 2006 — including the LEGS study and the MOVES trial (Hochberg et al., Annals of the Rheumatic Diseases, 2015; n=606) — found glucosamine plus chondroitin produced pain reduction comparable to celecoxib but with a high placebo response and without consistent superiority over placebo when funded independently of manufacturers. The 2005 Cochrane review of 20 RCTs (Towheed et al.) found glucosamine sulfate from the Rotta preparation outperformed placebo on pain and function, but non-Rotta preparations did not. Gregori et al.'s 2018 network meta-analysis in JAMA covered 47 long-duration RCTs (≥12 months) involving 22,037 patients and found uncertainty in pain estimates for nearly every comparator vs placebo, with only glucosamine sulfate retaining a significant pain estimate after sensitivity analysis.
Current Clinical Guidelines
OARSI, the ACR, EULAR, and NICE all conditionally recommend against routine use of glucosamine and chondroitin for OA, citing insufficient evidence of benefit. Exercise, weight management, and physical therapy have substantially stronger evidence for symptom management in OA than any supplement.
Sources
- Clegg DO, Reda DJ, Harris CL, et al. "Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis." New England Journal of Medicine, 2006;354(8):795–808. PMID 16495392. DOI: 10.1056/NEJMoa052771.
- Towheed TE, Maxwell L, Anastassiades TP, et al. "Glucosamine therapy for treating osteoarthritis." Cochrane Database of Systematic Reviews, 2005;(2):CD002946. PMID 15846645. DOI: 10.1002/14651858.CD002946.pub2.
- Hochberg MC, Martel-Pelletier J, Monfort J, et al. (MOVES Investigation Group). "Combined chondroitin sulfate and glucosamine for painful knee osteoarthritis: a multicentre, randomised, double-blind, non-inferiority trial versus celecoxib." Annals of the Rheumatic Diseases, 2016;75(1):37–44. PMID 25589511. DOI: 10.1136/annrheumdis-2014-206792.
- Gregori D, Giacovelli G, Minto C, et al. "Association of pharmacological treatments with long-term pain control in patients with knee osteoarthritis: a systematic review and meta-analysis." JAMA, 2018;320(24):2564–2579. PMID 30575881. DOI: 10.1001/jama.2018.19319.
- Bannuru RR, Osani MC, Vaysbrot EE, et al. "OARSI guidelines for the non-surgical management of knee, hip, and polyarticular osteoarthritis." Osteoarthritis and Cartilage, 2019;27(11):1578–1589. DOI: 10.1016/j.joca.2019.06.011.
Reviewed against 5 peer-reviewed sources.